Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515997 | 1.00 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2RAB9ALMNASIGMAR1 | |
| SCHEMBL2370627 | 1.00 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2RAB9ALMNASIGMAR1 | |
| SCHEMBL5967331 | 0.91 | PTGS1 (0.48) | ALDH1A1KMT2AMEN1CACNA1GFAAH | |
| SCHEMBL5967337 | 0.91 | PTGS1 (0.48) | ALDH1A1KMT2AMEN1CACNA1GFAAH | |
| SCHEMBL15506202 | 0.90 | TACR1 (0.45) | ALDH1A1SIGMAR1CACNA1GFAAH | |
| SCHEMBL15516356 | 0.90 | TACR1 (0.45) | ALDH1A1SIGMAR1CACNA1GFAAH | |
| SCHEMBL1915646 | 0.89 | NAAA (0.47) | ALDH1A1FAAHHPGD | |
| SCHEMBL7346791 | 0.89 | NAAA (0.47) | ALDH1A1FAAHHPGD | |
| SCHEMBL1915643 | 0.89 | NAAA (0.47) | ALDH1A1FAAHHPGD | |
| SCHEMBL7423431 | 0.89 | FAAH (0.48) | SIGMAR1KMT2AMEN1FAAHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015159170-A2 | IMPROVED PROCESS FOR THE SYNTHESIS OF 1-(4-METHOXYPHENYL) ETHYLAMINE AND ITS ISOMERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-10-22 | — | — | WO | disclosed |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| EP-2257167-B1 | 2-AMINOIMIDAZOLE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2015-07-22 | — | — | EP | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-8492387-B2 | 2-aminoimidazole beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2545037-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110612-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2011-09-15 | — | — | WO | disclosed |
| EP-1957470-A1 | PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS | Wyeth (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007067501-A1 | PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS | WYETH (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067501-A1 | PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS | WYETH (US) | 2007-06-14 | — | — | WO | disclosed |
| US-5438118-A | Peptide mimics having constrained peptide backbone | SMITHKLINE BEECHMAN CORP. (US) | 1995-08-01 | — | — | US | disclosed |
| EP-0559793-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| EP-0559793-A1 | HIV PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009297-A1 | HIV PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | ALDH1A1 2914/4885SMN1; SMN2 2779/4885RAB9A 2112/4885 |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | ALDH1A1 2914/4885SMN1; SMN2 2779/4885RAB9A 2112/4885 |
| US-20110224225-A1 | Inhibitors of protein kinases | CDK1, CDK2, CDK3 | ALDH1A1 2914/4885SMN1; SMN2 2779/4885RAB9A 2112/4885 |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | MAP2K4, MAP2K1, MAP2K6 | ALDH1A1 512/4885SMN1; SMN2 3365/4885RAB9A 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.